Search

Recursion Pharmaceuticals Inc

Закрыт

СекторЗдравоохранение

4 -8.26

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

3.93

Макс.

4.36

Ключевые показатели

By Trading Economics

Доход

-14M

-131M

Продажи

1.2M

7.7M

Прибыль на акцию

-0.25

Рентабельность продаж

-1,708.018

Сотрудники

600

EBITDA

-10M

-113M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+52.52% upside

Дивиденды

By Acuity

Следующий отчет о доходах

4 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

876M

2.6B

Предыдущая цена открытия

12.26

Предыдущая цена закрытия

4

Recursion Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

12 окт. 2026 г., 20:02 UTC

Recursion Pharmaceuticals Inc shares are sharply lower, continuing a downward trend since Friday, despite an early spike in today's trading session.

10 окт. 2026 г., 00:01 UTC

Recursion Pharmaceuticals Inc shares advanced during after-market hours on Friday, despite earlier pulling back from a session high.

9 окт. 2026 г., 23:01 UTC

Recursion Pharmaceuticals Inc is trading modestly higher in after-market hours, recovering from an earlier decline while remaining well above its 20-day moving average.

8 окт. 2026 г., 20:01 UTC

News
Correlated Moves

Recursion Pharmaceuticals faces downward pressure amid significant insider transactions, including a 50k share sale by Director Borgeson Blake on October 6.

7 окт. 2026 г., 23:05 UTC

Recursion Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of three consecutive sessions finishing lower since Wednesday's close.

6 окт. 2026 г., 20:02 UTC

Correlated Moves
Social Media
News

Recursion Pharmaceuticals Inc. shares fell amid sector declines, with attention on upcoming Phase 2 data for REC-4881 and ongoing trials for other candidates.

5 окт. 2026 г., 23:01 UTC

Recursion Pharmaceuticals Inc is declining in after-market trading, continuing lower since Monday's close, despite remaining above its 20-day moving average.

2 окт. 2026 г., 20:07 UTC

Correlated Moves

Recursion Pharmaceuticals Inc is trading higher, supported by a favorable market environment and positive sentiment following recent labor statistics.

1 окт. 2026 г., 23:01 UTC

Recursion Pharmaceuticals Inc saw modest gains in after-market hours, reaching a peak increase before settling lower, remaining near the upper end of its one-month range.

30 сент. 2026 г., 23:30 UTC

Correlated Moves

Recursion Pharmaceuticals Inc is trading higher in after-market hours, reflecting a broader market trend amid positive developments in technology and a revised U.S. GDP growth rate.

29 сент. 2026 г., 23:31 UTC

Recursion Pharmaceuticals Inc shares declined modestly in after-market trading, moving lower from Tuesday's close, currently around 0.74%, but above its 20-day moving average.

28 сент. 2026 г., 19:35 UTC

Social Media

Recursion Pharmaceuticals Inc shares fell amid commentary on its role in AI-driven drug design, reflecting a decline since Friday's close.

25 сент. 2026 г., 23:50 UTC

Recursion Pharmaceuticals Inc has advanced in after-market trading, remaining above its 20-day moving average and near the upper end of its one-month trading range.

24 сент. 2026 г., 20:07 UTC

Correlated Moves

Recursion Pharmaceuticals is advancing amid a positive biotechnology trend, gaining alongside the ARK Genomic Revolution ETF, which benefits from favorable news from its holdings.

23 сент. 2026 г., 23:21 UTC

Recursion Pharmaceuticals Inc is advancing in after-market trading, rising sharply since Wednesday's close and remaining above its 20-day moving average.

22 сент. 2026 г., 19:50 UTC

Social Media

Recursion Pharmaceuticals' stock is advancing after extending a data license agreement with Tempus AI, involving $42 million in committed payments over three years.

21 сент. 2026 г., 23:30 UTC

Recursion Pharmaceuticals Inc is declining in after-market trading, contrasting with recent gains, though it remains above its 20-day moving average.

19 сент. 2026 г., 00:01 UTC

Recursion Pharmaceuticals Inc is declining in after-market trading, moving lower since Friday's close, with notable momentum shifts observed during the session.

18 сент. 2026 г., 23:41 UTC

Recursion Pharmaceuticals Inc is declining in after-market trading, moving lower since Friday's close, despite remaining significantly above its 20-day moving average.

17 сент. 2026 г., 23:01 UTC

Correlated Moves

Recursion Pharmaceuticals Inc is trading modestly lower in after-market hours, moving in sympathy with Schrodinger Inc amid mixed economic indicators.

16 сент. 2026 г., 22:51 UTC

Correlated Moves

Recursion Pharmaceuticals Inc is moving higher in after-market trading, reflecting broader market gains following a sharp rise in U.S. retail sales in August.

15 сент. 2026 г., 23:02 UTC

Recursion Pharmaceuticals Inc. shares are higher in after-market trading, following the broader market's upward trend despite no specific company news.

14 сент. 2026 г., 20:08 UTC

Correlated Moves

Recursion Pharmaceuticals is gaining today, benefiting from Schrödinger's collaboration agreement with Tectora Therapeutics. Earlier, shares pulled back but have since recovered.

11 сент. 2026 г., 19:46 UTC

Recursion Pharmaceuticals Inc shares are higher during Friday's session, despite a slight pullback from earlier highs. No specific news was identified for the move.

10 сент. 2026 г., 23:16 UTC

No specific news was identified for Recursion Pharmaceuticals Inc. during after-market hours. The stock remained roughly flat since Thursday's close.

9 сент. 2026 г., 23:06 UTC

Recursion Pharmaceuticals Inc shares are higher in after-market trading, following a notable peak earlier in the session with no specific news identified.

8 сент. 2026 г., 22:51 UTC

Recursion Pharmaceuticals Inc shares are higher in after-market trading. The stock remains above its 20-day moving average and near the upper end of its one-month range.

4 сент. 2026 г., 20:08 UTC

Recursion Pharmaceuticals shares are higher today, continuing an upward trend since Thursday's close, amid broader market dynamics following a strong jobs report.

3 сент. 2026 г., 23:21 UTC

Correlated Moves

Recursion Pharmaceuticals Inc. shares declined in after-market trading, following a peak shortly after the market closed and amid broader market weakness.

2 сент. 2026 г., 23:06 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market trading. The decline comes amid a weaker ADP private payrolls report impacting overall market sentiment.

Сравнение c конкурентами

Изменение цены

Recursion Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

52.52% рост

Прогноз на 12 месяцев

Средняя 6.65 USD  52.52%

Максимум 8 USD

Минимум 5.3 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Recursion Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

5 ratings

2

Покупка

3

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.